PDF(Pubmed)
Abstract：
Prostate cancer is one of the most common malignant diseases in men, and it contributes significantly to the increased mortality rate in men worldwide. This study aimed to review the roles of p300 and TMPRSS2 (transmembrane protease, serine 2) in the AR (androgen receptor) pathway as they are closely related to the development and progression of prostate cancer. This paper represents a library-based study conducted by selecting the most suitable, up-to-date scientific published articles from online journals. We focused on articles that use similar techniques, particularly those that use prostate cancer cell lines and immunohistochemical staining to study the molecular impact of p300 and TMPRSS2 in prostate cancer specimens. The TMPRSS2:ERG fusion is considered relevant to prostate cancer, but its association with the development and progression as well as its clinical significance have not been fully elucidated. On the other hand, high p300 levels in prostate cancer biopsies predict larger tumor volumes, extraprostatic extension of disease, and seminal vesicle involvement at prostatectomy, and may be associated with prostate cancer progression after surgery. The inhibition of p300 has been shown to reduce the proliferation of prostate cancer cells with TMPRSS2:ETS (E26 transformation-specific) fusions, and combining p300 inhibitors with other targeted therapies may increase their efficacy. Overall, the interplay between the p300 and TMPRSS2 pathways is an active area of research.
摘要：
前列腺癌是男性最常见的恶性疾病之一，它极大地促进了全世界男性死亡率的上升。本研究旨在综述p300和TMPRSS2(跨膜蛋白酶，丝氨酸2)在AR(雄激素受体)通路中因为它们与前列腺癌的发生、发展亲密相干。本文代表了一项基于图书馆的研究，通过选择最合适的，在线期刊上发表的最新科学文章。我们专注于使用类似技术的文章，特别是那些使用前列腺癌细胞系和免疫组织化学染色来研究p300和TMPRSS2在前列腺癌标本中的分子影响的人。TMPRSS2：ERG融合被认为与前列腺癌有关，但其与发展和进展的关系及其临床意义尚未完全阐明。另一方面,前列腺癌活检中的高p300水平预测更大的肿瘤体积，疾病的前列腺外延伸，前列腺切除术的精囊受累，并且可能与手术后的前列腺癌进展有关。p300的抑制已被证明可以减少TMPRSS2：ETS（E26转化特异性）融合的前列腺癌细胞的增殖，并且将p300抑制剂与其他靶向疗法结合使用可能会提高其疗效。总的来说,p300和TMPRSS2途径之间的相互作用是一个活跃的研究领域。
